[CAS NO. 220201-34-3] Talaporfinsodium
PRODUCTS SPECIFICATIONS [220201-34-3]
DESCRIPTION [220201-34-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 799.69 |
| Molecular Formula | C38H37N5Na4O9 |
| SMILES | O=C(O[Na])C[C@@H](C(O[Na])=O)NC(C/C1=C2[C@@H](CCC(O[Na])=O)[C@H](C)C(/C=C3C(C)=C(C=C)/C(N/3)=C/C(C(C)=C/4CC)=NC4=C/C5=C(C)C(C(O[Na])=O)=C1N5)=N\2)=O |
1 Publications Citing Use of MCE
Summary
Talaporfin (ME2906) sodium is a chlorin based photosensitizer . Talaporfin sodium can be used for the research of various cancers by using photodynamic therapy (PDT) [1] .
In Vivo
Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs)
[1]
.
Labeling in vivo:
1. Use the rat brain tumor model produced by the inoculation of resuspended tumor cells into the frontal rat brain. Feed animals according to your normal protocol.
2. Intravenous injection of 5 mg/kg body weight talaporfin sodium, the concentration of the talaporfin sodium is 5 mg/1 ml 0.9% saline.
3. For the control group, intraperitoneal injection of 100 mg/kg body weight 5-ALA, the concentration of the 5-ALA is 20 mg/1 ml 0.9% saline.
4. Obtain the tissue samples corresponding to the tumor (or edema) brain tissue with 5 mm thickness.
5. The samples are well homogenized with 1 ml of 100% dimethyl sulfoxide (DMSO) and the 100 ul aliquots of the supernatant are put into each well of a 96-well plate.
6. Measure the relative fluorescence intensities of the samples by using a microplate readerin emission wavelength of 670 ±10 nm. The relative fluorescence intensities of the samples (a.u.) were normalized to the relative fluorescence intensities per 1 g-weight of the samples (a.u.).
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Rat brain tumor model [1] |
| Dosage: | 5 mg/kg |
| Administration: | Intravenous injection |
| Result: | Showed high fluorescence intensity and retention in brain tumor differentiated from vasogenic edema. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00355355 | Light Sciences Oncology |
Carcinoma, Hepatocellular|Liver Neoplasms
|
July 2006 | Phase 3 |
| NCT00083785 | Light Sciences LLC |
Liver Metastasis|Colorectal Neoplasms|Liver Neoplasms|Neoplasm Metastasis
|
May 2004 | Phase 2 |
| NCT00440310 | Light Sciences Oncology |
Liver Metastases|Colorectal Neoplasms|Neoplasm Metastasis|Neoplasm Recurrence, Local
|
February 2007 | Phase 3 |
| NCT00709488 | Light Sciences Oncology |
Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms
|
June 2008 | Phase 1 |
| NCT02326454 | Light Sciences Oncology|Mundipharma Research Limited |
Benign Prostatic Hyperplasia
|
November 2014 | Phase 2 |
| NCT00122876 | Light Sciences Oncology|Light Sciences LLC |
Carcinoma, Hepatocellular|Liver Neoplasms
|
April 2005 | Phase 1|Phase 2 |
| NCT01924273 | University of California, Irvine|Beckman Laser Institute University of California Irvine |
Port-Wine Stain
|
June 2013 | Phase 1 |
| NCT00918034 | Light Sciences Oncology |
Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms
|
May 2009 | Phase 2 |
| NCT00068068 | Light Sciences LLC |
Liver Metastasis|Colorectal Neoplasms|Liver Neoplasms|Neoplasm Metastasis
|
October 2003 | Phase 2 |
| NCT00102115 | Light Sciences LLC |
Macular Degeneration|Choroidal Neovascularization
|
December 2004 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 25 mg/mL ( 31.26 mM ; Need ultrasonic)
DMSO : 2 mg/mL ( 2.50 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2505 mL | 6.2524 mL | 12.5048 mL |
| 5 mM | 0.2501 mL | 1.2505 mL | 2.5010 mL |
| 10 mM | 0.1250 mL | 0.6252 mL | 1.2505 mL |
